Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Safety Study of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

This study has been completed.
Information provided by (Responsible Party):
Repros Therapeutics Inc. Identifier:
First received: February 9, 2012
Last updated: June 27, 2014
Last verified: June 2014
ZA-300 is meant to determine the safety profile of Androxal (enclomiphene citrate) in men with secondary hypogonadism.

Condition Intervention Phase
Secondary Hypogonadism
Drug: Androxal
Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open Label, Escalating Dose, 6 Month Phase III Safety Study Of Enclomiphene Citrate in the Treatment of Men With Secondary Hypogonadism

Resource links provided by NLM:

Further study details as provided by Repros Therapeutics Inc.:

Primary Outcome Measures:
  • Change From Baseline in Total Morning Testosterone at 26 Weeks [ Time Frame: 6 months ]
    Changes in values from baseline of total morning testosterone levels at Week 26

  • Change From Baseline in LH [ Time Frame: 6 months ]
    Mean change from baseline in LH at end of treatment (26 weeks)

  • Absolute Values of Morning Testosterone [ Time Frame: 6 months ]
    Absolute values of morning testosterone at end of treatment (26 weeks)

  • Mean Change From Baseline FPG [ Time Frame: 6 months ]
    Mean changes in Fasting Plasma Glucose from baseline to end of treatment (26 weeks)

  • Change From Baseline in BMI [ Time Frame: 6 months ]
    Mean change from baseline in BMI at end of treatment (26 weeks)

  • Change From Baseline in FSH [ Time Frame: 6 months ]
    Change from baseline in FSH at end of treatment (26 weeks)

Enrollment: 499
Study Start Date: May 2012
Study Completion Date: October 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Androxal 12.5 mg
Androxal 12.5 mg daily
Drug: Androxal
Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated
Other Name: Enclomiphene citrate
Experimental: Androxal 25 mg
Androxal 25 mg daily
Drug: Androxal
Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated
Other Name: Enclomiphene citrate

Detailed Description:
This study is a phase III, open label safety study with a six month active dosing period. All subjects will be started at 12.5 mg Androxal and titrated to 25 mg if needed. Safety will be assessed by physical and visual acuity exams, slit lamp eye exams, clinical laboratory tests and adverse event reporting.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Secondary hypogonadal males between the ages of 18 and 65
  2. Men currently using topical testosterone products should wash-out for at least 7 days before Visit 1.
  3. All clinical laboratory tests within normal ranges (any clinically significant deviation of laboratory results will require approval of sponsor)
  4. Previously or concurrently diagnosed as having secondary hypogonadism and confirmed with morning testosterone level < 350 ng/dL for men age < 55 and < 300ng/dl for men age 55-65
  5. LH < 15mIU/mL (at Visit 1 only)
  6. Ability to complete the study in compliance with the protocol
  7. Ability to understand and provide written informed consent.

Exclusion Criteria:

  1. Use of an injectable pelleted testosterone within 6 months prior to study (men currently on topical testosterone products may be enrolled in the study after a 7-day washout period).
  2. Use testosterone injection, spironolactone, cimetidine, Clomid, 5α-reductase inhibitors, hCG, androgen, estrogen, anabolic steroid, DHEA, or herbal hormone products during the study
  3. Use of Clomid in the past year
  4. Uncontrolled hypertension based on the Investigator's assessment at baseline. Subjects treated for Type II diabetes will be allowed into the study.
  5. A hematocrit ≥ 51% or a hemoglobin ≥ 17 g/dL
  6. Clinically significant abnormal findings on screening examination, based on the Investigator's assessment.
  7. Use of an investigational drug or product, or participation in a drug or medical device research study within 30 days prior to receiving study medication.
  8. Known hypersensitivity to Clomid
  9. Symptomatic cataracts (nuclear sclerosis cataract or cortical cataract grade > 2 based on 0-4 scale or any trace of posterior subcapsular cataract)
  10. Any condition which in the opinion of the investigator would interfere with the participant's ability to provide informed consent, comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he took part in the study
  11. Irreversibly infertile or compromised fertility (cryptorchism, Kallman Syndrome, primary hypogonadism, or tumors of the pituitary)
  12. Current or history of breast cancer
  13. Current or history of prostate cancer or a suspicion of prostate disease unless ruled out by prostate biopsy, or a PSA > 3.6
  14. Presence or history of known hyperprolactinemia with or without a tumor
  15. Chronic use of medications use such as glucocorticoids
  16. Chronic use of narcotics
  17. Subjects know to be positive for HIV
  18. End stage renal disease
  19. Subjects with cystic fibrosis (mutation of the CFTR gene)
  20. Enrollment in a previous Androxal study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01534208

United States, Arizona
Clinical Research Advantage
Glendale, Arizona, United States, 85306
Clinical Research Advantage
Phoenix, Arizona, United States, 85020
United States, Arkansas
Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States, 72205
United States, California
Catalina Research Institute
Chino, California, United States, 91710
SC Clinical Research
Garden Grove, California, United States, 92844
South Orange County Endocrinology
Laguna Hills, California, United States, 92653
Anthony Mills, MD
Los Angeles, California, United States, 90069
SD Uro-Research
San Diego, California, United States, 92103
San Diego Sexual Medicine
San Diego, California, United States, 92120
SC Clinical Research
Santa Ana, California, United States, 92703
West Coast Clinical Research
Tarzana, California, United States, 91356
United States, Colorado
Clinical Research Advantage
Colorado Springs, Colorado, United States, 80906
Clinical Research Advantage
Colorado Springs, Colorado, United States, 80922
United States, Florida
Meridien Research
Bradenton, Florida, United States, 34208
Florida Fertility Institute
Clearwater, Florida, United States, 33759
Therafirst Medical Center
Fort Lauderdale, Florida, United States, 33308
East Coast Institute for Clinical Research
Jacksonville, Florida, United States, 32204
East Coast Institute for Research
Jacksonville, Florida, United States, 32204
East Coast Institute for Research
Jacksonville, Florida, United States, 32258
Cetero Research
Miami Gardens, Florida, United States, 33169
Well Pharma Medical Research
Miami, Florida, United States, 33143
DMI Research
Pinellas Park, Florida, United States, 33782
Ebon Bourne, MD
Plantation, Florida, United States, 33324
Meridien Research
St. Petersburg, Florida, United States, 33709
United States, Maryland
IRC Clinics
Towson, Maryland, United States, 21204
United States, New Jersey
Premier Urology Associates
Lawrenceville, New Jersey, United States, 08648
United States, Texas
Advances in Health
Houston, Texas, United States, 77030
Breco Research
Sugar Land, Texas, United States, 77479
Center of Reproductive Medicine
Webster, Texas, United States, 77598
United States, Utah
Lone Peak Family Medicine
Draper, Utah, United States, 84020
Granger Medical Clin ic
Riverton, Utah, United States, 84065
Sponsors and Collaborators
Repros Therapeutics Inc.
Study Chair: Joseph S Podolski Repros Therapeutics Inc.
  More Information

Additional Information:
Responsible Party: Repros Therapeutics Inc. Identifier: NCT01534208     History of Changes
Other Study ID Numbers: ZA-300
Study First Received: February 9, 2012
Results First Received: June 27, 2014
Last Updated: June 27, 2014

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes
Gonadal Disorders
Endocrine System Diseases
Citric Acid
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Fertility Agents, Female
Fertility Agents
Reproductive Control Agents
Selective Estrogen Receptor Modulators
Estrogen Receptor Modulators
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017